Scandion Oncology A/S – Flagging message
Scandion Oncology A/S (”Scandion Oncology” or “the Company”) hereby announces that due to dilution in connection to the recently announced rights issue, that was fully subscribed, the shareholders Saniona AB, Jan Stenvang and Nils Brünner passes the 5 percent limit. Each party's votes and capital in the Company previously exceeded 5 percent. Following the completion of the rights issue, the parties' votes and capital will be less than 5 percent.Jan Stenvang, Chief Technology Officer in Scandion Oncology, previously owned 1,391,064 shares (approximately 6.5 percent), and will after